Adriamycin
Liver And Intrahepatic Bile Duct Neoplasm
Explore 21 assets in Liver And Intrahepatic Bile Duct Neoplasm →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Children's National Research Institute
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04791228CT.gov A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | — | Withdrawn | — | — | — |
NCT04008797CT.gov A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | — | Active Not Recruiting | — | — | — |
NCT02536183CT.gov A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | — | Terminated | — | — | — |
NCT02181075CT.gov Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours | — | Completed | — | — | — |
NCT01281943CT.gov Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer | — | Withdrawn | — | — | — |
NCT00441376CT.gov A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver And Intrahepatic Bile Duct Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Children's National Research Institute | P2 | B · 62 |
| Irinotecan | Tehran University of Medical Sciences | P4 | BBB |
| Chlorhexidine | Changhua Christian Hospital | P4 | BB |
| Albumin Aggregated | Sirtex Medical | P4 | BB |
| Talaporfin | Light Sciences Oncology | P3 | BB |
| Oxaliplatin | Shanghai Zhongshan Hospital | P4 | BB |
| Triglycerides,Medium Chain | Wei Zhou | P4 | BB |
| Hep-V Vax | University of Oxford | P4 | BB |
| Sorafenib | Sichuan Cancer Hospital and Research Institute | P3 | BB |
+41 more in the Liver And Intrahepatic Bile Duct Neoplasm cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Liver And Intrahepatic Bile Duct Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-liver-and-intrahepatic-bile-duct-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →